ReachRxResearch
Home
Research
Sign Up
A critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis
Back to Research Hub
  1. Home
  2. Research Hub
  3. A critical appraisal of guidelines and r…

A critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis

Clinical Kidney Journal·October 9Open Access
Urology & NephrologyLimited evidenceANCA-Associated VasculitisSystematic Review / Guideline Appraisal

Summary

View source

What was studied

Eleven currently available clinical guidelines for ANCA-associated vasculitis (AAV) were appraised using the AGREE II instrument (23 criteria across 6 domains) by 4 independent reviewers to identify gaps and suggest improvements.

Key findings

The average AGREE II score across all 11 guidelines was 4.5 ± 0.8 out of 7.0; the British Society for Rheumatology 2025 guideline scored highest (5.8/7.0) and was the only one unanimously recommended for use. The weakest domain was Applicability (D5), with poor scores for implementation tools, resource/cost implications, and audit criteria; patient involvement (D2) was also consistently lacking.

Study limitations

Only 4 reviewers appraised the guidelines, which limits the breadth of perspective; the AGREE II tool evaluates guideline quality and reporting rather than clinical content accuracy or outcomes; and the appraisal reflects guidelines available at a single point in time.

Clinical implications

Clinicians managing AAV should preferentially consult the BSR 2025 guidelines, which currently meet the highest methodological standards. Guideline developers should prioritize incorporating patient perspectives and practical implementation tools in future AAV guideline updates.

Caveats

  • Applicability scores were uniformly low across guidelines, meaning even the top-rated BSR 2025 guideline may offer limited practical implementation support at the point of care
  • The sample is limited to 11 guidelines reviewed by only 4 appraisers, which may not fully capture inter-rater variability across broader reviewer pools
  • This study appraises guideline quality and reporting methodology (using AGREE II), not clinical treatment outcomes — findings should not be interpreted as evidence about AAV treatment efficacy or safety

Related Questions

Explore related topics

Which ANCA-associated vasculitis guidelines are most up to date and recommended for clinical use?How does the BSR 2025 AAV guideline compare to EULAR recommendations for induction and maintenance therapy?What are best practices for incorporating patient preferences into rheumatology and nephrology clinical guidelines?

Publication Details

Year
2026
Journal
Clinical Kidney Journal
Sample Size
n=11
Source
View article
Keep scrolling
More content below.
Up Next